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Dear Editor, 
We read with interest Platt et al.’s commentary1 on our economic analysis2 and agree with many of 
the points raised; particularly the urgent need to ‘avert the growing health crisis faced by [people 
who inject drugs] PWID in the United Kingdom’. We agree that the provision of detachable low dead 
space syringes (LDSS) is one of several diverse strategies needed to address hepatitis C virus (HCV) 
transmission, and more broadly, to reduce social exclusion and health and social inequalities among 
PWID.  
We show in economic models that replacing detachable high dead space syringes (HDSS) with 
detachable LDSS at needle and syringe programmes (NSP) is a cost-saving approach to reducing HCV 
transmission among PWID. This research forms part of a multi-disciplinary body of evidence 
supporting the roll out of LDSS. In addition, we have previously demonstrated that LDSS use is 
associated with reduced HCV risk in the UK, have shown why some PWID use LDSS and some do 
not,3 and critically shown that NSPs in general are a highly cost-effective way of reducing the spread 
of HCV among PWID4.  
We agree that other initiatives are needed to deal with the added risks associated with structural 
disablers such as homelessness and incarceration. Nevertheless, in the context of funding cuts to 
services across the health and social care landscape, commissioners and policy makers need clear 
evidence on cost-saving strategies to guide decision making. As well as cost efficiencies, the benefits 
of introducing detachable LDSS include the wide-scale potential to reduce harm while requiring 
minimal change to service users’ behaviour5. Furthermore, a complete switch in equipment available 
across all NSP providers would reach all PWID, including the most marginalised who may not access 
services directly (i.e. rely on secondary distribution from peers). 
Many analyses are limited by the absence of marginalised groups in research, not just modelling. We 
have looked into this issue in previous and on-going modelling of the risks associated with recent 
imprisonment7 and people experiencing homelessness8, and other modelling considering the range 
of factors that increase mortality among opioid users9. Furthermore, while QALYs can be limited, 
they can also be used to account for factors such as homelessness and recent incarceration which 
can reduce the quality of life of PWID10. Therefore, while we agree with Platt et al. and others6 that 
modelling  studies can simplify human behaviour, have a narrow viewpoint and are reliant on the 
data available, they are still a crucial piece of the jigsaw for intervention implementation and 
investment.  
In response to the research methodology critique, we did not use estimates of syringe coverage for 
Bristol. Instead, we assumed a stable epidemic (consistent with recent data) with current levels of 
syringe distribution (HDSS and LDSS) to estimate how much transmission through syringe sharing 
would decrease by if the majority of HDSS were swapped with detachable LDSS. On generalisability, 
the strength and robustness of our results suggest it will be cost saving even if done in pharmacy 
NSP and other settings. In addition, static NSP is still offered in various parts of the UK. One of the 
authors visited several of these during the implementation phase of this project (described below). 
These visits revealed that not all NSP are operated by dedicated NSP workers and highlighted the 
need for updated standardised training which is now being developed in collaboration with a 
specialist social enterprise. Bristol is unusual in that all injecting equipment is delivered through a 
single contract, making impact easier to assess. 
Finally, we support the assertion that successful intervention implementation requires both service 
user and provider input. Using co-production methods, we worked closely with PWID as co-
designers of harm reduction materials to implement our research in a way that supports the uptake 
of LDSS equipment by NSP and service users11. The materials are freely available to download 
(https://www.exchangesupplies.org/shopdisp_low_dead_space_needles_and_syringes_what_and_
why_booklet.php) and have been widely distributed. 
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